Assuming that the basic criteria for investment are met and that the company has decided that it is seeking equity investment then the following process will be undertaken.
- The executive will review the business plan and let the company know whether or not the proposal will be considered further.
- If it is not suitable for Archangels, we will try and suggest other potential investment sources.
- If it is considered to be suitable for further investigation, then a meeting will be held with the management team to discuss the plan and the needs of the company.
- If there is still interest, then some basic due diligence will be undertaken and other members of the syndicate may become involved in the assessment.
- The company will be asked to present to the Board of Archangels.
- The investment and other resource needs of the company will be discussed and agreed and an outline deal structure will be set out.
- Appropriate due diligence and preparation of standard investment agreements etc will commence in parallel.
- The company will normally be asked to present to a forum of interested potential investor members.
- A non-executive chairman and a further non-executive director will be identified and agreed with the management team.
- Any debt or grant requirements will be finalised.
- Completion of the investment will proceed.
- Archangels endeavour to keep deal costs low, charging upon completion of a successful funding round a research fee to cover due diligence and the initial investment. We also use low cost standard legal agreements which keep the legal fees payable by the company for completion of an investment to a minimum. There is a modest annual fee to the companies to cover the costs of ongoing monitoring and liaison.
Cable gets to grips with Great British design
25 Jun 2014MGB Biopharma Expands Scientific Advisory Board (SAB) with Medical Microbiologist Dr Stephanie Dancer
Business Secretary, Vince Cable, saw bionic limbs, an airship and a model of a hypersonic aircraft when he launched the ‘Pioneering Great British Products' report at Liverpool's Life Sciences University Technical College.
23 Jun 2014Touch Bionics founder receives Queen’s Honour
MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that Dr Stephanie Dancer, an internationally renowned medical microbiologist, has joined its scientific advisory board (SAB). She will help oversee the development of MGB Biopharma’s lead antibiotic candidate, MGB-BP-3. An oral formulation of MGB-BP-3 is ready to enter Phase I development for Clostridium difficile, and an iv presentation is in late preclinical development for Gram-positive hospital acquired infections.
16 Jun 2014Touch Bionics introduces new control method for bionic hand
David Gow named Commander of the Order of the British Empire
Touch Bionics, a provider of world-leading prosthetic technologies, is proud to announce that the company's founder, David Gow, was named Commander of the Order of the British Empire (CBE) in this year's Queen's Birthday Honours list.
14 May 2014Technology Strategy Board Biomedical Catalyst Award to Drive Development of Novel System to Assess and Manage Tooth Decay (Dental Caries)
Livingston, Scotland – May 14, 2014 – Touch Bionics, a provider of world-leading prosthetic technologies, has announced the introduction of the latest enhancements to the i-limb™ ultra revolution at the OTWorld 2014 International Congress taking place in Leipzig, Germany.
09 May 2014
Calcivis, a medical devices company focused on revolutionising the management of tooth decay, today announces that it has received a prestigious Biomedical Catalyst award co-funding a £0.5m development programme and raised a further £0.8m in equity funding from existing investors Archangel Informal Investment and the Scottish Investment Bank, the investment arm of Scottish Enterprise.